Abaloparatide

Mechanism

A newer bone-building injection similar to teriparatide but based on PTHrP instead of PTH. It builds new bone with potentially less calcium elevation and bone resorption. FDA-approved for osteoporosis. Some evidence it's more effective at the hip than teriparatide.

Effects

## Detailed Effects — Abaloparatide ### Skeletal System — Bone Formation [Tier 1] - Synthetic 34-amino acid analog of PTHrP(1-34) with 8 amino acid substitutions for enhanced receptor selectivity and metabolic stability. - Preferentially binds PTH1R in the RG (active) conformation over the R0 (inactive) conformation — produces more transient cAMP signaling than teriparatide. - This transient signaling profile preferentially activates osteoblastic bone formation (anabolic) with less stimulation of osteoclastic bone resorption (catabolic) compared to teriparatide. - **ACTIVE Trial (Leder et al., JAMA 2015; Miller et al., JAMA 2016, n=2,463)**: 86% relative risk reduction in new vertebral fractures vs placebo at 18 months. 43% reduction in non-vertebral fractures. Significant BMD increases at spine (+9.2%), total hip (+3.4%), and femoral neck (+3.6%). - Hip BMD gains may be superior to teriparatide — ACTIVE trial showed significantly greater total hip BMD increase with abaloparatide vs teriparatide at 18 months (+3.4% vs +1.7%). - Onset of BMD gain is rapid — measurable changes at 6 months. ### Cardiovascular System [Tier 1] - Lower incidence of hypercalcemia compared to teriparatide (3.4% vs 6.4% in ACTIVE trial) — due to more transient PTH1R activation producing less calcium mobilization from bone. - Transient increases in heart rate observed post-injection (tachycardia in 2% of patients). - No significant effect on blood pressure in clinical trials. ### Metabolic Effects [Tier 1-2] - Less hypercalcemia means less nausea and better tolerability than teriparatide. - No clinically significant effects on renal function. - Does not appear to affect glucose metabolism.

Practitioner Guide

## Practitioner Guide — Abaloparatide ### Dosing & Administration - **Dose**: 80 mcg subcutaneous injection once daily. - **Device**: Tymlos prefilled pen — 30 doses per pen. Pen delivers fixed 80 mcg dose. - **Injection site**: Periumbilical region of the abdomen. Rotate sites daily. Clean with alcohol swab. - **Timing**: Administer at approximately the same time each day. No specific meal timing required. - **Duration**: FDA-approved for up to 2 years. The 2-year limit is based on the osteosarcoma signal seen in animal studies with prolonged high-dose PTH-analog exposure (though this risk with abaloparatide at human doses is considered very low). ### Practitioner Sequencing Strategy (Bone Agents) This is critical — the ORDER in which you use anabolic and antiresorptive agents matters enormously: **BEST PRACTICE: Anabolic First, Antiresorptive Second** 1. **Start with an anabolic agent** (abaloparatide or teriparatide) for up to 2 years to BUILD new bone. 2. **Then transition to an antiresorptive** (denosumab, zoledronic acid, or oral bisphosphonate) to MAINTAIN the gains. 3. **Never skip the antiresorptive follow-up** — BMD gains from anabolic agents are rapidly lost without consolidation therapy. Bone loss begins within months of stopping. **Why Anabolic First?** - Starting with a bisphosphonate first, then switching to an anabolic, produces SMALLER BMD gains than anabolic-first (DATA trial, Cosman et al., Lancet 2011). - Prior bisphosphonate use blunts the bone-forming response to PTH analogs for the first 6-12 months. - If a patient is already on a bisphosphonate: stop the bisphosphonate and start the anabolic. The bisphosphonate's long skeletal half-life provides some residual antiresorptive effect during the transition. **Abaloparatide vs Teriparatide: When to Choose Which** - Abaloparatide may be preferred when: hip BMD gain is a priority (better hip data), lower hypercalcemia risk desired, or the patient had nausea with teriparatide. - Teriparatide may be preferred when: longer track record desired (approved since 2002), more extensive data in glucocorticoid-induced osteoporosis, or hypoparathyroidism is a co-indication. - Both agents are equivalent for vertebral fracture reduction. **Transitioning Between Anabolics** - Switching from teriparatide to abaloparatide (or vice versa) mid-course is not well-studied but is done clinically when a patient does not tolerate one agent. - No washout period needed — can switch directly. ### Transitioning to Antiresorptive After Abaloparatide - **Denosumab (Prolia)**: Preferred transition agent. ACTIVExtend trial showed continued BMD gains when abaloparatide patients switched to denosumab for 2 additional years. Total 4-year vertebral fracture reduction: 87%. - **Zoledronic acid**: Annual IV infusion. Good alternative if patient prefers less frequent dosing. - **Oral bisphosphonates (alendronate, risedronate)**: Acceptable but may provide less consolidation than denosumab or zoledronic acid. - **Timing**: Start antiresorptive within 1 month of completing abaloparatide. Do not leave a gap. ### Supplement Synergies - **Calcium**: 1,000-1,200 mg/day total (diet + supplement). Essential for bone mineralization. Do not exceed — excess calcium does not improve outcomes and may increase cardiovascular risk. - **Vitamin D3**: Maintain 25(OH)D level 40-60 ng/mL. Most patients need 2,000-5,000 IU/day. Check level at baseline and 3 months. - **Vitamin K2 (MK-7)**: 100-200 mcg/day — activates osteocalcin for calcium deposition into bone matrix. Synergistic with D3. - **Magnesium**: 400-600 mg/day — cofactor for vitamin D activation and bone crystal formation. - **Collagen peptides**: 10-15 g/day — may support organic bone matrix formation (emerging Tier 2 data). ### Storage & Handling - Tymlos pen: Refrigerate (2-8°C). After first use, can store at room temperature (20-25°C) for up to 30 days. - Do not freeze. Discard if frozen. - Each pen contains 30 doses. Discard pen after 30 days even if doses remain. ### Monitoring - DXA scan at baseline, 1 year, and 2 years. - Serum calcium at 1 month (check for hypercalcemia — rare but possible). - 25(OH)D level at baseline. - P1NP (bone formation marker) at baseline and 3 months — should increase significantly, confirming anabolic response.

Dosing Protocols

Contraindications & Cautions

• hard stop — Bone metastases
  PTHrP analog-stimulated osteoblast activity could accelerate tumor growth in skeletal metastases.
  Action: Do not use with bone metastases or skeletal malignancy.
• hard stop — Paget disease of bone
  Same class contraindication as teriparatide. High bone turnover state increases osteosarcoma risk with PTHrP analog use.
  Action: Do not use. Contraindication per Tymlos prescribing information.
• hard stop — Unexplained elevated alkaline phosphatase
  Unexplained ALP elevation may indicate occult bone disease or malignancy requiring investigation before PTHrP analog use.
  Action: Do not use until ALP elevation is fully evaluated.
• hard stop — Prior radiation therapy to skeleton
  Prior skeletal radiation increases osteosarcoma risk. PTHrP analog use further elevates this risk. Labeled contraindication.
  Action: Do not use. Labeled contraindication.
• hard stop — Hypercalcemia
  Abaloparatide may worsen hypercalcemia. Pre-existing hypercalcemia is a contraindication.
  Action: Do not use. Evaluate and correct hypercalcemia first.
• hard stop — Open epiphyses
  Contraindicated in patients with open epiphyses due to osteosarcoma risk in growing bone.
  Action: Do not use in patients with open epiphyses. Labeled contraindication.
• hard stop — Pregnancy
  No adequate human data. Contraindicated per labeling.
  Action: Do not use during pregnancy.
• hard stop — Under 18 years of age
  Contraindicated in patients with open epiphyses.
  Action: Do not provide to individuals under 18.
• caution — Use exceeding 2 years
  Same 2-year maximum as teriparatide due to osteosarcoma signal in animal studies. Cumulative duration with teriparatide should also not exceed 2 years.
  Action: Do not exceed 2 years cumulative PTH/PTHrP analog use. Transition to antiresorptive therapy afterward.

Evidence

• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE)

  Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C (2016) — JAMA — PMID: 27163987

  Abaloparatide (PTHrP analog) 80 mcg daily reduced new vertebral fractures by 86% (0.58% vs 4.22% placebo) and nonvertebral fractures by 43% over 18 months in postmenopausal osteoporosis. Comparable BMD gains to teriparatide with potentially less hypercalcemia. Faster onset of BMD increase at total hip vs teriparatide. FDA-approved as Tymlos in 2017.

  strong

Research Summary

## Research Summary — Abaloparatide ### Tier 1: Randomized Controlled Trials - **ACTIVE Trial (Miller et al., JAMA 2016, n=2,463)**: Pivotal Phase 3 RCT. Abaloparatide 80 mcg/day vs teriparatide 20 mcg/day vs placebo x 18 months. Abaloparatide: 86% vertebral fracture risk reduction vs placebo, 43% non-vertebral fracture reduction. Significantly greater total hip BMD increase vs teriparatide (+3.4% vs +1.7%, p<0.05). Lower hypercalcemia rate (3.4% vs 6.4%). - **ACTIVExtend (Bone et al., J Clin Endocrinol Metab 2018, n=1,139)**: 2-year extension — patients completing ACTIVE switched to alendronate 70 mg/week. Prior abaloparatide patients maintained and extended BMD gains. 87% vertebral fracture risk reduction maintained at 43 months. - **ATOM Trial (Cosman et al., Lancet Diabetes Endocrinol 2024)**: Abaloparatide in men with osteoporosis — significant BMD improvements at spine and hip, confirming efficacy in male osteoporosis. ### Tier 2: Systematic Reviews & Meta-Analyses - Network meta-analyses comparing bone anabolics: abaloparatide and teriparatide are similar for vertebral fracture reduction, abaloparatide may have an edge at the hip (indirect comparisons). - Systematic reviews confirm lower hypercalcemia risk with abaloparatide vs teriparatide. - Position in treatment guidelines: AACE and Endocrine Society now recommend anabolic-first strategies for high-risk osteoporosis patients. ### Tier 3: Case Reports & Practitioner Protocols - Practitioners widely report faster onset of BMD response vs bisphosphonates. - Real-world sequencing data confirms anabolic-first → antiresorptive is superior to reverse sequencing. - Some practitioners use abaloparatide specifically for patients with poor hip BMD given the ACTIVE trial hip data. ### Gaps - No head-to-head trial with romosozumab (another anabolic agent). - Optimal duration of subsequent antiresorptive therapy after completing abaloparatide course is unknown. - Repeat courses of abaloparatide (after completing 2 years and a period on antiresorptive) have not been studied in RCTs. ### Active Trials - Abaloparatide transdermal patch (wearable ABTT device) in Phase 3 — would eliminate daily injections. - Ongoing real-world studies of sequential therapy outcomes. - Studies in fracture healing and glucocorticoid-induced osteoporosis.